Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polychlorinated Biphenyls | 12 | 2025 | 46 | 4.730 |
Why?
|
| Environmental Pollutants | 10 | 2025 | 201 | 3.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2022 | 760 | 1.540 |
Why?
|
| Gene Expression | 6 | 2025 | 701 | 1.540 |
Why?
|
| Gene Expression Profiling | 4 | 2026 | 704 | 1.430 |
Why?
|
| Metabolic Diseases | 2 | 2023 | 40 | 1.430 |
Why?
|
| RNA, Untranslated | 1 | 2026 | 50 | 0.940 |
Why?
|
| Maternal Exposure | 1 | 2025 | 57 | 0.900 |
Why?
|
| Environmental Exposure | 3 | 2022 | 256 | 0.880 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2025 | 192 | 0.810 |
Why?
|
| Fatty Liver | 1 | 2023 | 77 | 0.770 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2022 | 21 | 0.730 |
Why?
|
| Dyslipidemias | 1 | 2022 | 48 | 0.730 |
Why?
|
| Slovakia | 6 | 2025 | 9 | 0.720 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 224 | 0.670 |
Why?
|
| MicroRNAs | 1 | 2026 | 518 | 0.620 |
Why?
|
| Pakistan | 3 | 2022 | 20 | 0.500 |
Why?
|
| Pilot Projects | 3 | 2026 | 760 | 0.500 |
Why?
|
| Humans | 23 | 2026 | 43102 | 0.470 |
Why?
|
| Chronic Disease | 1 | 2017 | 549 | 0.430 |
Why?
|
| Endocrine Disruptors | 1 | 2014 | 44 | 0.400 |
Why?
|
| Mutagens | 2 | 2010 | 74 | 0.390 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2022 | 20 | 0.380 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 1001 | 0.330 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1070 | 0.310 |
Why?
|
| District of Columbia | 2 | 2022 | 80 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2026 | 968 | 0.290 |
Why?
|
| Prostatic Neoplasms | 3 | 2026 | 1092 | 0.260 |
Why?
|
| Neoplasms | 1 | 2017 | 1377 | 0.250 |
Why?
|
| Protein Biosynthesis | 1 | 2007 | 132 | 0.250 |
Why?
|
| Child | 3 | 2022 | 3443 | 0.240 |
Why?
|
| Elasticity | 1 | 2025 | 53 | 0.240 |
Why?
|
| Fetal Blood | 1 | 2025 | 48 | 0.230 |
Why?
|
| Obesity | 1 | 2014 | 1151 | 0.230 |
Why?
|
| Male | 9 | 2026 | 23409 | 0.230 |
Why?
|
| Homeodomain Proteins | 1 | 2026 | 150 | 0.220 |
Why?
|
| Stress, Mechanical | 1 | 2025 | 164 | 0.220 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2025 | 61 | 0.220 |
Why?
|
| Trans-Activators | 1 | 2026 | 192 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2025 | 213 | 0.220 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2015 | 247 | 0.220 |
Why?
|
| Adaptation, Physiological | 1 | 2025 | 143 | 0.220 |
Why?
|
| Epigenesis, Genetic | 2 | 2026 | 291 | 0.210 |
Why?
|
| Adult | 4 | 2026 | 13872 | 0.210 |
Why?
|
| Liver | 1 | 2007 | 511 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2026 | 403 | 0.200 |
Why?
|
| Cell Movement | 3 | 2026 | 655 | 0.200 |
Why?
|
| Nerve Tissue Proteins | 2 | 2023 | 386 | 0.200 |
Why?
|
| Female | 8 | 2026 | 24698 | 0.200 |
Why?
|
| Case-Control Studies | 1 | 2026 | 1285 | 0.190 |
Why?
|
| Infant, Newborn | 1 | 2025 | 972 | 0.190 |
Why?
|
| PPAR alpha | 1 | 2022 | 42 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 310 | 0.180 |
Why?
|
| Triglycerides | 1 | 2022 | 147 | 0.180 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 138 | 0.180 |
Why?
|
| Guanine | 1 | 2021 | 44 | 0.170 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 40 | 0.170 |
Why?
|
| Apoptosis | 3 | 2010 | 1568 | 0.170 |
Why?
|
| Cholesterol | 1 | 2022 | 232 | 0.170 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2020 | 13 | 0.170 |
Why?
|
| Lipids | 1 | 2022 | 256 | 0.170 |
Why?
|
| Halogenation | 1 | 2020 | 19 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2022 | 1546 | 0.170 |
Why?
|
| Genomics | 1 | 2022 | 293 | 0.160 |
Why?
|
| Blood Glucose | 1 | 2022 | 389 | 0.160 |
Why?
|
| ras Proteins | 1 | 2020 | 54 | 0.160 |
Why?
|
| Hepatocytes | 2 | 2010 | 80 | 0.160 |
Why?
|
| Pregnancy | 1 | 2025 | 1772 | 0.160 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2019 | 3 | 0.150 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2019 | 5 | 0.150 |
Why?
|
| DNA Fragmentation | 2 | 2010 | 98 | 0.140 |
Why?
|
| Middle Aged | 3 | 2026 | 12222 | 0.140 |
Why?
|
| Printing | 1 | 2017 | 8 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2017 | 1759 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2017 | 2157 | 0.120 |
Why?
|
| Cell Line, Tumor | 4 | 2026 | 2676 | 0.120 |
Why?
|
| Cell Survival | 2 | 2010 | 945 | 0.120 |
Why?
|
| Rural Population | 1 | 2018 | 373 | 0.110 |
Why?
|
| Adolescent | 2 | 2017 | 6081 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 1028 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1078 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1234 | 0.100 |
Why?
|
| Prevalence | 1 | 2018 | 1612 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 515 | 0.100 |
Why?
|
| Hexachlorobenzene | 1 | 2011 | 3 | 0.090 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2011 | 6 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1542 | 0.090 |
Why?
|
| Hazardous Substances | 1 | 2011 | 19 | 0.090 |
Why?
|
| United States | 1 | 2022 | 5205 | 0.090 |
Why?
|
| Trypan Blue | 1 | 2010 | 2 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 54 | 0.080 |
Why?
|
| Lethal Dose 50 | 1 | 2010 | 32 | 0.080 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 44 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3156 | 0.080 |
Why?
|
| Cell Line | 2 | 2010 | 1410 | 0.080 |
Why?
|
| Immunoblotting | 2 | 2007 | 181 | 0.080 |
Why?
|
| Cell Death | 1 | 2010 | 278 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 5080 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 532 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2026 | 1455 | 0.060 |
Why?
|
| Animals | 2 | 2020 | 16992 | 0.060 |
Why?
|
| Myosin Type II | 1 | 2025 | 17 | 0.060 |
Why?
|
| Aged | 1 | 2018 | 8214 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2007 | 383 | 0.060 |
Why?
|
| Time Factors | 2 | 2007 | 1857 | 0.060 |
Why?
|
| Phosphorylcholine | 1 | 2004 | 8 | 0.050 |
Why?
|
| Staurosporine | 1 | 2004 | 38 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1003 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2004 | 195 | 0.050 |
Why?
|
| CpG Islands | 1 | 2023 | 109 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 220 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2023 | 321 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2021 | 39 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2011 | 64 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2025 | 735 | 0.040 |
Why?
|
| Histones | 1 | 2021 | 197 | 0.040 |
Why?
|
| Methylcholanthrene | 1 | 2019 | 4 | 0.040 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2019 | 8 | 0.040 |
Why?
|
| Body Weight | 1 | 2021 | 429 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2023 | 1271 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 495 | 0.040 |
Why?
|
| Actins | 1 | 2019 | 164 | 0.040 |
Why?
|
| Disease | 1 | 2011 | 21 | 0.020 |
Why?
|
| Paraquat | 1 | 2010 | 20 | 0.020 |
Why?
|
| Oxidants | 1 | 2010 | 42 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 149 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 256 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 266 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 652 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 863 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 6644 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 25 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 25 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 346 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 458 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 883 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1124 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 1019 | 0.010 |
Why?
|